Education
About Us
Working with TipRanks
Follow Us
ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
Top Page
ENDRA Life Sciences
(NASDAQ:NDRA)
34Underperform
Positive Factors
Management Leadership
The appointment of Alexander Tokman as acting CEO, with over 24 years of experience in technology development and commercialization, could drive significant growth.
Strategic Direction
The company's new strategic direction focuses on developing the TAEUS system as a biomarker solution for early detection and management of metabolic diseases.
Negative Factors
Revenue Generation
ENDRA, being a late-stage medical device development and early-stage commercialization company, currently generates no revenues.
ENDRA Life Sciences (NDRA) vs. S&P 500 (SPY)
Market Cap
$3.45M
Dividend YieldN/A
Average Volume (3M)286.86K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth71.89%
CountryUS
Employees21
SectorHealthcare
Sector Strength56
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-934.10
Shares Outstanding562,213
10 Day Avg. Volume467,245
30 Day Avg. Volume286,855
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.60
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$50.00Price Target Upside714.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
ENDRA Life Sciences Business Overview & Revenue Model
Company DescriptionENDRA Life Sciences (NDRA) is a medical technology company that operates in the healthcare sector. The company is focused on developing innovative diagnostic tools, particularly in the field of liver disease. ENDRA's flagship product is the Thermo Acoustic Enhanced Ultrasound (TAEUS) system, which aims to provide a cost-effective and non-invasive solution for assessing liver fat content, aiding in the management of conditions such as non-alcoholic fatty liver disease (NAFLD). The TAEUS system is designed to work alongside standard ultrasound systems, enhancing their capabilities with ENDRA's proprietary technology.
How the Company Makes MoneyENDRA Life Sciences generates revenue primarily through the sale and licensing of its TAEUS system. As the company targets healthcare providers, hospitals, and clinics, its revenue model relies on the adoption of its technology within the medical community. ENDRA may also engage in strategic partnerships or collaborations with other medical technology companies or research institutions to expand the application and reach of its technology. Additionally, the company might explore opportunities to generate revenue through service agreements or support contracts related to its TAEUS system. However, detailed financial data or specific partnership information is not available.
ENDRA Life Sciences Financial Statement Overview
Summary
ENDRA Life Sciences faces significant financial challenges, as evidenced by its lack of revenue generation and ongoing losses. While the company has managed to maintain liquidity through financing, its long-term sustainability hinges on achieving revenue growth and improving operational efficiencies.Income Statement
The company has consistently reported zero revenue, resulting in an inability to calculate profit margins. The net losses have persisted over the years, showing no signs of revenue generation or operational profitability. This reflects significant challenges in achieving market traction or product monetization.―
Balance Sheet
The debt-to-equity ratio is relatively low, indicating manageable leverage. However, the shrinking stockholders' equity and continuous losses have weakened the balance sheet over time. The company has managed to maintain cash reserves through financing activities, but overall financial stability remains a concern.30
Cash Flow
The company experiences negative operating cash flow, indicating a lack of operational cash generation. Although financing activities have provided necessary liquidity, the consistent negative free cash flow highlights a challenging cash management situation.―
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -275.45K | -234.26K | -224.41K | -165.25K | -115.01K | EBIT |
| -10.52M | -13.16M | -11.50M | -11.50M | -10.84M | EBITDA |
| -9.78M | -12.94M | -11.01M | -11.33M | -10.84M | Net Income Common Stockholders |
| -10.06M | -13.20M | -11.19M | -11.97M | -15.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.83M | 4.89M | 9.46M | 7.23M | 6.17M | Total Assets |
| 6.75M | 9.27M | 12.87M | 8.76M | 7.18M | Total Debt |
| 394.40K | 546.63K | 678.96K | 685.47K | 707.07K | Net Debt |
| -2.44M | -4.34M | -8.78M | -6.54M | -5.47M | Total Liabilities |
| 1.10M | 2.07M | 2.09M | 1.60M | 2.42M | Stockholders Equity |
| 5.66M | 7.20M | 10.78M | 7.17M | 4.76M |
| Cash Flow | Free Cash Flow | |||
| -9.58M | -12.97M | -11.17M | -10.82M | -8.63M | Operating Cash Flow |
| -9.55M | -12.77M | -11.12M | -10.77M | -8.59M | Investing Cash Flow |
| -24.72K | -202.58K | -45.00K | -51.33K | -43.59K | Financing Cash Flow |
| 7.52M | 8.40M | 13.40M | 11.88M | 8.34M |
ENDRA Life Sciences Technical Analysis
Positive
6.14
Price Trends
4.19
Positive
4.77
Positive
19.42
Negative
Market Momentum
0.58
Negative
63.22
Neutral
78.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NDRA, the sentiment is Positive. The current price of 6.14 is above the 20-day moving average (MA) of 4.40, above the 50-day MA of 4.19, and below the 200-day MA of 19.42, indicating a neutral trend. The MACD of 0.58 indicates Negative momentum. The RSI at 63.22 is Neutral, neither overbought nor oversold. The STOCH value of 78.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NDRA.
ENDRA Life Sciences Risk Analysis
ENDRA Life Sciences disclosed 46 risk factors in its most recent earnings report. ENDRA Life Sciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ENDRA Life Sciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.35B | 3.81 | -42.57% | 2.86% | 17.10% | 1.33% | |
42 Neutral | $5.79M | ― | -100.40% | ― | -58.46% | 47.98% | |
39 Underperform | $2.08M | ― | ― | 0.31% | 44.72% | ||
39 Underperform | $3.12M | ― | -191.51% | ― | -6.42% | 24.85% | |
34 Underperform | $3.45M | ― | -280.02% | ― | ― | 71.89% | |
26 Underperform | $4.45M | ― | -74.17% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
NDRA
ENDRA Life Sciences
6.14
-558.58
-98.91%
AWHL
Aspira Women's Health
0.07
-3.14
-97.82%
APDN
Applied DNA Sciences
0.89
-180.61
-99.51%
CHEK
Check-Cap
0.89
-1.31
-59.55%
ISPC
iSpecimen
1.25
-4.27
-77.36%
ENDRA Life Sciences Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q2-2024)
| % Change Since: 51.60%|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment Neutral
The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.Q2-2024 Updates
Positive Updates
Enhanced Management Team
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
Strategic Regulatory Changes
The company is implementing a new FDA regulatory strategy, transitioning from retrospective data to a hypothesis-driven, statistically-powered prospective clinical trial, increasing the number of subjects from 20 to about 250 to achieve statistical power.
Significant Reduction in Operating Expenses
ENDRA reduced operating expenses by over $3 million, approximately a 26% reduction on an annualized basis, without impacting key deliverables, such as clinical data collection for FDA submission.
Strong Intellectual Property Portfolio
The patent portfolio now includes 81 issued patents globally, with 5 additional patents issued in Q2 2024, covering thermoacoustic technology and other applications.
Positive FDA Alignment
Positive feedback from an FDA meeting confirmed alignment on product configuration, clinical study design, and regulatory pathway, setting a clear path for the TAEUS liver device.
Negative Updates
Reverse Stock Split Challenges
The reverse stock split intended to maintain NASDAQ listing was derailed by high volume of exercised warrants, resulting in trading below $1, creating uncertainty for the company's stock performance.
Limited Cash Runway
As of June 30, 2024, ENDRA had cash and cash equivalents of $6.4 million, projected to fund operations only into the first half of 2025, highlighting potential future financial constraints.
Company Guidance
During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.